Superluminal Medicines secures $60M for AI-driven obesity drug
Boston-based Superluminal Medicines, which uses AI and machine learning for drug discovery, closed a $60 million Series B round on September 3, 2026. The financing was oversubscribed, indicating strong investor interest in its obesity-focused pipeline.
Sources: unite.ai
“The oversubscribed round reflects growing investor confidence in AI-driven drug discovery, particularly for obesity—a market expanding beyond GLP-1 therapies.”
Read the original reporting
The outlets below did the original reporting.
Related briefs
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.